Galen

by Ibex Medical Analytics  · Based in Israel → — Trusted cancer diagnostics for all
Oncology Pathology
Website
Claim this tool
Is this the maker? Claim the company →

Not disclosed
Regulatory Status Disclosed

Overview

Galen, by Ibex Medical Analytics, is an AI-powered pathology platform designed to assist pathologists in detecting cancer and over a hundred other diagnostic features across multiple tissue types. The platform, also referred to as the Ibex AI Platform, offers FDA-cleared solutions such as Galen Prostate, Galen Breast, and Galen Gastric, which are developed from extensive datasets of over 10 million slides and trained by expert pathologists using deep learning technologies. It aims to enhance diagnostic accuracy, improve efficiency, and provide a superior user experience in routine clinical practice. Galen acts as a ‘second pathologist’ or ‘AI consultant,’ offering prospective quality control and aiding in the identification of small or higher-grade cancers that might otherwise be missed. The platform is designed to boost physician confidence, ensure patient safety, and deliver accurate, timely, and personalized cancer diagnoses.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered detection and grading of cancer regions
  • Detection of over a hundred diagnostic features in multiple tissue types
  • Clinically-proven accuracy and enhanced efficiency
  • Developed from rich datasets (over 10 million slides) and deep learning algorithms
  • Prospective and real-time quality control for diagnostic confidence
  • Identification of small foci and higher-grade cancers that may be missed
  • Specific solutions for Prostate, Breast, and Gastric tissue analysis (Galen Prostate, Galen Breast, Galen Gastric)
  • AI Explainability with visual heat maps to pinpoint findings
  • Prioritization of cases based on disease/tumor type and pathologist experience
  • Streamlining immunohistochemistry (IHC) workflows

Use Cases

  • Assisting pathologists in primary diagnosis of prostate cancer
  • Assisting pathologists in primary diagnosis of breast cancer
  • Assisting pathologists in primary diagnosis of gastric cancer
  • Providing a 'second opinion' or 'AI consultant' for increased diagnostic confidence
  • Identifying potentially missed small foci or higher-grade cancers
  • Improving diagnostic accuracy and reducing turnaround times in pathology laboratories
  • Optimizing pathology workflows and boosting productivity
  • Supporting drug development through biomarker assessment and clinical trial optimization for biopharma partners

What Physicians Need to Know

Key Capabilities
AI-powered detection and grading of cancer (prostate, breast, gastric), identification of over 100 diagnostic features, case prioritization, real-time quality control, AI explainability with heat maps, streamlining immunohistochemistry (IHC) workflows, and automated HER2/ER/PR/Ki67 scoring.
Clinical Utility
Improves diagnostic accuracy, reduces major discrepancy rates (e.g., 29% reduction in breast cancer diagnosis), enhances pathologist efficiency, increases diagnostic confidence, enables 100% quality control on prostate and breast biopsies, and supports early detection of cancer.
Integration Options
Available as a standalone solution or integrated with third-party digital pathology software, scanning platforms (e.g., Philips IntelliSite Pathology Solution), and Laboratory Information Systems (LIS) via an open API and DICOM support.
Compliance Status
Galenu2122 Prostate (now Ibex Prostate Detect in the US) is CE marked under IVDR and registered with the UK MHRA. It has also received FDA 510(k) clearance in the US for identifying cases initially diagnosed as benign for further review. Galen Breast and Galen Gastric solutions are in the process of migrating under the IVDR certificate, and some solutions are Research Use Only (RUO) in the United States.
Pricing Model
Operates on a SaaS (Software as a Service) model based on annual usage. Some customers have noted the cost can be prohibitive for universal adoption across all cases.
User Experience
Reported to improve user experience and employee satisfaction, increase diagnostic confidence, and provide visual heat maps and points of interest (POIs) for enhanced review. Customers generally report positive experiences with knowledgeable staff.
Support Quality
Customers report positive experiences with knowledgeable staff and timely support responses.
Implementation Complexity
Requires digital transformation of the pathology department, early engagement with IT and LIS providers, and training of staff pathologists with appropriate ergonomic setups.
Evidence Base
Demonstrated outstanding outcomes in multi-site, independent clinical studies. Algorithms are trained on extensive datasets (over 2 million to 10 million labeled images) from diverse labs and geographies, manually annotated by senior pathologists. Studies are published in peer-reviewed journals and presented at global conferences.
Physician Tip

Embrace Galen (now Ibex) as a powerful decision-support tool to augment diagnostic expertise, not replace it. Leverage its AI-powered heatmaps and alerts for robust quality control and to prioritize complex cases, which can significantly reduce turnaround times. Always be aware of the specific regulatory status (e.g., CE-IVDR, FDA clearance, RUO) of each solution in your region to ensure appropriate clinical application. Collaborate closely with your IT department and the vendor for seamless integration into existing digital pathology workflows and Laboratory Information Systems (LIS) to maximize efficiency. Utilize the AI's objective quantification capabilities for IHC markers like HER2, ER/PR, and Ki67 to enhance reproducibility and consistency in your reporting.

Galen (now Ibex) is designed for flexible integration within existing digital pathology ecosystems. It features an open API and actively partners with leading providers of Laboratory Information Systems (LIS), Image Management Systems (IMS), and Whole Slide Imaging (WSI) Scanners. The platform supports DICOM, which facilitates interoperability and enables efficient, end-to-end clinical workflows. Achieving seamless integration is crucial for fully realizing the benefits of AI in diagnostic workflows, including automated high-quality insights and enhanced patient safety.

Details

Category Oncology AI, Pathology AI
Pricing Not disclosed — Not disclosed
DeploymentIntegrated into digital pathology workflows
Compliance
BAA AvailableUnknown AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status 1 AI-estimated

Ibex offers FDA-cleared solutions for cancer detection in multiple tissue types. Some solutions are FDA cleared, while others are Research Use Only (RUO) in the United States. The platform also holds CE-IVD certification and is registered with UK MHRA, TGA in Australia, and ANVISA in Brazil.
Integrations
EHR Not specified
Specialties Oncology, Pathology

What the Web Says

Galen, an AI-powered platform by Ibex Medical Analytics, assists pathologists in detecting and grading various cancers, including prostate, breast, and gastric. It aims to improve diagnostic accuracy, increase efficiency, and reduce turnaround times in pathology labs. The platform has been integrated into routine clinical practice in several pathology labs worldwide.

Overall: Positive

Strengths

  • Improved diagnostic accuracy and reduced discrepancy rates
  • Increased pathologist efficiency and reduced turnaround times
  • Real-time quality control and identification of missed cancer cases
  • Intuitive and easy-to-use software
  • AI explainability with heat maps that pinpoint cancer and other findings
  • Ability to prioritize work by disease/tumor type and pathologists' experience levels

Limitations

  • Solution can be cost-prohibitive
  • Could integrate better with certain systems
  • Some initial reservations about digital pathology and AI from pathologists

Based on reviews from: Ibex Medical Analytics Galen AI Pathology 2023, Scanning whole slide images with the Ibex Galen AI breast algorithm, The Galen Platform Reviews - 2026 - Slashdot, Israeli startup Ibex Medical aims to transform cancer diagnostics with AI tech, Ibex Medical Analytics: An In-Depth Guide to the Future of AI Pathology - Skywork, Validation and three years of clinical experience in using an artificial intelligence algorithm as a second read system for prostate cancer diagnosisu2014real-world experience - PMC, Galen Breast or SOC - Ibex Medical Analytics, Ibex Reports Excellent Outcomes for AI-supported Diagnosis of Breast Cancer, Galen Prostate shows potential to enhance prostate cancer detection - Urology Times, Ibex Medical Analytics - Sectra Amplifier Marketplace, Reject corporate AI. Promote AI within the pathology community. - Reddit, Delphine Raoux, MD: Efficiency gains in using AI-solution in primary diagnosis of prostate biopsies - IBEX, VIDEO: Ibex Medical Analytics CEO shares his vision for AI-based cancer diagnostics, Prof. Stuart Schnitt on AI in pathology and how Ibex's Galen transforms the way pathologists work - YouTube, Excellent outcomes for Ibex Breast - Ibex Medical Analytics, Is Ibex in Monroeville legit? : r/pittsburgh - Reddit, Ibex Medical Analytics

Last updated: 2026-07-22

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Galen

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

PR Newswire
Ibex's Galenu2122 Prostate Becomes First Standalone AI-Powered Cancer Diagnostics Solution to Obtain CE Mark Under the IVDR
Ibex Medical Analytics announced that its Galenu2122 Prostate solution received CE Mark under the IVDR, making it the first standalone AI-based cancer diagnostics product of its kind to meet the new EU regulatory standard. This certification signifies the platform's adherence to rigorous safety, quality, and performance criteria for primary diagnosis of prostate biopsies.
2023-02
PR Newswire
Ibex Announces Galenu2122 3.0 Cancer Diagnostics Platform
Ibex Medical Analytics launched Galenu2122 3.0, an updated AI-powered cancer diagnostics platform with enhanced detection capabilities and features for prostate, breast, and gastric biopsies. The platform is CE-Marked and aims to improve diagnostic accuracy and efficiency for pathologists worldwide.
2022-09
The Royal College of Pathologists
Scanning whole slide images with the Ibex Galen AI breast algorithm
Dr. David Bailey reported on the Northwest Anglia NHS Foundation Trust's successful trial of the Ibex Galen AI breast algorithm, which demonstrated significant benefits in workload and performance, including improved prostate biopsy turnaround times. The trial showed undeniable benefits to workload and performance despite initial reservations about digital pathology and AI.
2026-04
BioPharma APAC
Ibex Granted FDA Breakthrough Device Designation - BioPharma APAC
Ibex Medical Analytics' Galenu2122 AI-powered platform received Breakthrough Device Designation from the U.S. FDA, which will expedite its clinical review and regulatory approval. This designation acknowledges the platform's potential to more effectively diagnose life-threatening diseases like cancer.
unknown
Ibex Medical Analytics
New release of Ibex Medical Analytics AI-powered platform to accelerate advancements in cancer diagnostics
Ibex Medical Analytics unveiled the latest advancements in its AI-powered product platform, including enhanced breast cancer detection with automated HER2 immunohistochemistry (IHC) scoring and improved interoperability. The platform, previously known as Galen, also received IVDR certification.
2024-09
Targeted Oncology
FDA Grants 510(k) Clearance to Ibex Prostate Detect AI for Prostate Cancer | Targeted Oncology
The FDA granted 510(k) clearance to Ibex Prostate Detect software (formerly Galen Second Read), an AI-powered digital pathology solution for identifying small and rare prostate cancers in tissue biopsies. This marks Ibex Medical Analytics' first regulatory clearance and highlights the AI's ability to detect cancers potentially missed by initial pathologist review.
2025-02
PMC (PubMed Central)
Validation and three years of clinical experience in using an artificial intelligence algorithm as a second read system for prostate cancer diagnosisu2014real-world experience - PMC
A study published in PMC validated the Galenu2122 Prostate AI algorithm for prostate cancer detection in Puerto Rican men, demonstrating high diagnostic accuracy and utility for Gleason grading. The algorithm, used as a second-read system, processed over 122,000 slides and 9,200 cases over three years, showing a significant impact on diagnosis.
unknown
BioSpace
Ibex and Alverno Laboratories Sign Multi-Year, Multi-Tissue Expansion Agreement of AI for Cancer Diagnosis | BioSpace
Alverno Laboratories expanded its agreement with Ibex Medical Analytics to deploy the Galenu2122 suite of AI solutions across its entire network in Illinois and Indiana, supporting pathologists in diagnosing breast, prostate, and gastric cancers. This large-scale implementation aims to improve productivity, reduce operational costs, and enhance cancer care.
2023-03

Videos

Product demos, reviews, and walkthroughs for Galen.

View all on YouTube

Frequently Asked Questions

Galen AI, specifically Abridge's platform, integrates into existing EHR workflows, particularly deeply with Epic, by using ambient listening to capture patient-clinician conversations. It then generates structured clinical notes in real-time, allowing physicians to focus on patient interaction rather than extensive documentation. Additionally, it can produce patient after-visit summaries and is expanding to offer clinical decision support by surfacing relevant medical literature.
Galen AI by Abridge is designed to be HIPAA compliant, providing a Business Associate Agreement (BAA) to covered entities. All patient data is encrypted both in transit and at rest, stored in secure, US-based data centers, and protected by strict internal access-control policies.
Several alternatives to Galen AI (Abridge) exist for clinical documentation, including DeepScribe, Suki, Nuance Dragon Medical One (DAX Copilot), Freed, and Glass Health. Some newer platforms like S10.AI and RevMaxx aim to offer more comprehensive workflow automation beyond just transcription, such as preparing orders or suggesting billing codes.
Galen AI (Abridge) operates on an enterprise-only model, meaning pricing is not publicly transparent and is negotiated through direct sales with healthcare organizations. Estimates suggest costs around $2,500 per clinician per year, or potentially $250-$800 per provider per month, making it primarily suited for large health systems rather than individual clinicians or small practices.
A primary limitation of Galen AI (Abridge) is its enterprise-only focus, which excludes individual clinicians and smaller practices from direct access. While it integrates with various EHRs, its deepest and most seamless integration is with Epic, potentially leading to a less optimized experience for non-Epic health systems. Furthermore, it primarily functions as a documentation tool and may lack broader functionalities like AI reception, fax management, or comprehensive clinical reasoning support offered by some competitors.

Related Tools

Surgical Reality Viewer
Surgical Reality
Oncology AI
Surgical Reality offers CE- and FDA-certified AI-powered 3D medical imaging and surgical planning software that transforms CT scans into patient-specific 3D models for thoracic surgery, enhancing precision in complex lung procedures.
Cancer Copilot
Color Health
Oncology AI
Color Health's Cancer Copilot, built with OpenAI, helps oncologists and clinicians identify and order workup needs for recently diagnosed patients, aiming to speed up time to cancer treatment. This AI tool is designed to expand cancer expertise, speed decisions, and improve care, reducing a two-hour clinical task to 10 minutes with over 95% validated accuracy.
Cercare Medical Oncology Virtual Expert
Cercare Medical
Neurology AI
Cercare Medical's Oncology Virtual Expert is an AI-powered brain tumor segmentation module that provides fast, consistent, and semi-automated tumor analysis from standard MRI data, designed for on-premise deployment within existing clinical radiology workflows.
Synapse Lung Nodule AI
Fujifilm Corporation
Oncology AI
Fujifilm's Synapse Lung Nodule AI is an AI software algorithm for detecting pulmonary nodules on CT imaging, aiming to support early detection and treatment of lung cancer.
On request
RadOncAI
Informai (for RadOncAI product) / Global Network for AI in Radiation Oncology (for RadoncAI.net)
Oncology AI
RadOncAI is an AI solution by Informai designed to optimize and enhance radiation oncology workflows, improving efficiency and accuracy in treatment planning and delivery.
FAITH project (Fatigue Therapy – AI-supported Diagnosis and Therapy of Tumour-associated Fatigue Syndrome)
Fimo Health GmbH (Consortium Leader)
Mental & Behavioral Health AI
The FAITH project is developing an AI-based solution for the diagnosis and therapy of tumor-associated fatigue syndrome in cancer patients. It uses wearable sensors, a smartphone app, and artificial intelligence to provide individualized therapy recommendations and monitor mental health.

See all Oncology AI tools →

More from Ibex Medical Analytics

Galen™ Second Read™
Ibex Medical Analytics
Oncology AI
Galen™ Second Read™ (now Ibex Prostate Detect in the US) is an AI-powered digital pathology solution by Ibex Medical Analytics that analyzes prostate core needle biopsies to detect potentially missed cancers, providing pathologists with alerts and heatmaps to enhance diagnostic accuracy and streamline workflows.
Contact for pricing

View company profile →

Suggest an Edit → | Last Verified: 2026-04-21 | First Added: 2026-04-21

Investors who backed Galen

Funded through the company that built this tool.

Octopus Ventures
VC T1
London, United Kingdom
$1M-$5M
Octopus Ventures is one of Europe’s largest and most active early-stage venture firms, deploying over £200 million annually across health, fintech, deep…
AI/ML in Healthcare Biotech
fresh.fund
VC AI T3
Jerusalem, Israel
<$250k
Fresh.fund is a Jerusalem-based seed fund built around a specific edge: it writes the first institutional checks into student-led and academic-led ventures…
AI/ML in Healthcare Diagnostics
Kamet Ventures
Startup Studio T3
Paris, France
unknown
Kamet Ventures is the venture builder and investor arm of AXA, the French global insurance group, with a thesis built around building…
AI/ML in Healthcare Care Delivery / Tech-Enabled Services
AI Tool Finder
AI-powered search. Results may not be comprehensive.